Press coverage about Crispr Therapeutics (NASDAQ:CRSP) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Crispr Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.3911457911834 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Piper Jaffray Reiterates “Buy” Rating for Crispr Therapeutics (CRSP) (americanbankingnews.com)
- CRISPR Therapeutics (CRSP) Presents at Needham and Company 17th Annual Healthcare Conference – Slideshow (seekingalpha.com)
- Crispr Therapeutics (CRSP) Upgraded to Buy by SunTrust Banks (americanbankingnews.com)
- CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property (finance.yahoo.com)
- Crispr Therapeutics (CRSP) Stock Rating Upgraded by TheStreet (americanbankingnews.com)
Several research analysts recently weighed in on the stock. Piper Jaffray reissued a “buy” rating and set a $22.75 price objective (down previously from $39.00) on shares of Crispr Therapeutics in a research note on Wednesday, January 10th. JMP Securities initiated coverage on shares of Crispr Therapeutics in a research note on Thursday, March 8th. They set an “outperform” rating and a $69.00 price objective on the stock. SunTrust Banks restated a “buy” rating and set a $65.00 target price on shares of Crispr Therapeutics in a report on Friday, March 9th. Citigroup raised their target price on shares of Crispr Therapeutics from $20.00 to $51.00 and gave the stock a “neutral” rating in a report on Wednesday, February 28th. Finally, TheStreet upgraded shares of Crispr Therapeutics from a “d+” rating to a “c” rating in a report on Friday, March 16th. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $59.54.
In other Crispr Therapeutics news, major shareholder Aktiengesellschaft Bayer acquired 527,472 shares of the stock in a transaction dated Friday, January 5th. The shares were bought at an average cost of $22.75 per share, for a total transaction of $11,999,988.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tyler Dylan-Hyde sold 31,000 shares of Crispr Therapeutics stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $22.72, for a total transaction of $704,320.00. The disclosure for this sale can be found here. Insiders have sold a total of 265,091 shares of company stock worth $6,876,323 over the last 90 days. Corporate insiders own 39.98% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/29/crispr-therapeutics-crsp-earning-somewhat-favorable-media-coverage-analysis-finds/1971284.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.